Argent Biopharma Ltd
RGT
Company Profile
Business description
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.
Contact
295 Rokeby Road
Suite 1
SubiacoWA6008
AUST: +61 865552950
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.50 | 41.90 | -0.47% |
| CAC 40 | 7,818.28 | 32.15 | -0.41% |
| DAX 40 | 24,295.93 | 55.11 | 0.23% |
| Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
| FTSE 100 | 9,138.37 | 76.88 | 0.85% |
| HKSE | 25,383.07 | 284.11 | -1.11% |
| NASDAQ | 21,057.96 | 37.94 | 0.18% |
| Nikkei 225 | 41,450.36 | 375.98 | -0.90% |
| NZX 50 Index | 12,855.10 | 49.97 | 0.39% |
| S&P 500 | 6,363.35 | 4.44 | 0.07% |
| S&P/ASX 200 | 8,670.10 | 39.30 | -0.45% |
| SSE Composite Index | 3,593.38 | 12.35 | -0.34% |